CRISPR Therapeutics AG
CRSPNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $4.77B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $44.12$75.06
- Volume (live)
- -
- Avg. volume (3M)
- 1.73M
CRISPR Therapeutics (CRSP) Stock Price & Financial Analysis
CRISPR Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $48.02 - $49.68 |
|---|---|
| 52-Week High | $75.06 |
| 52-Week Low | $44.12 |
| Open | $49.31 |
| Volume (last close) | 2.12M |
| Average Volume (3M) | 1.73M |
| Revenue (TTM) | 13.21M |
|---|---|
| Net Income (TTM) | -475.90M |
| Free Cash Flow (TTM) | -373.80M |
| EPS (TTM) | −$5.02 |
| Profit Margin | -3602.33% |
| Operating Margin | -4044.66% |
| Return on Equity (ROE) | -27.25% |
| Debt to Equity | 0.35 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 4.77B |
|---|---|
| Shares Outstanding | 96.51M |
| Price to Sales (P/S) | 360.82 |
| Price to Book (P/B) | 2.73 |
| EV/EBITDA | -10.50 |
| 50-Day MA | $54.80 |
|---|---|
| 200-Day MA | $53.08 |
| 1-Year Change | −25.62% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
CRISPR Therapeutics at a Glance
As of the Oct 23, 2026 close, CRISPR Therapeutics (CRSP) has a market capitalization of $4.77B. The stock trades at 360.8× sales. Over the trailing twelve months it lost $475.90M on revenue of $13.21M and burned $373.80M of free cash flow. Revenue fell 65.4% year over year.
As of its latest reported balance sheet, it holds $291.34M in cash and securities against $604.84M of debt, a net debt position of $313.51M.
CRISPR Therapeutics does not currently pay a dividend.
The share price is down 25.6% over the past year. At $49.39 (the Oct 23, 2026 close) it sits within its 52-week range of $44.12 to $75.06, below its 200-day moving average of $53.08.
Based on 17 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $71.17, 44.1% above the Oct 23, 2026 close.
Frequently Asked Questions About CRISPR Therapeutics
What is the current stock price for CRSP?
As of the Oct 23, 2026 close, CRSP stock trades at $49.39. The 52-week range is $44.12–$75.06, with a day range of $48.02–$49.68.
What is the P/E ratio for CRSP?
The P/E ratio (Price-to-Earnings) for CRSP is shown in the Key Statistics section. This valuation metric helps compare CRISPR Therapeutics AG to industry peers.
Does CRSP pay dividends?
CRISPR Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CRSP?
Based on ratings from 17 professional analysts over the last 90 days, the consensus for CRSP is Buy. The average 12-month price target is $71.17, a 44.1% upside from the Oct 23, 2026 close of $49.39.
What is the market cap of CRSP?
As of the Oct 23, 2026 close, CRISPR Therapeutics's market capitalization is $4.77B, classifying it as a mid-cap company. CRISPR Therapeutics operates in the Healthcare sector within the Biotechnology industry.